First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia

被引：6

作者：

Argyropoulos, Kimon V. ^{[1
]}

Lia, M. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Program Immunol, 408 East 69th St, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, 1275 York Ave, New York, NY 10065 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 05期

关键词：

Waldenstrom macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors; B-CELL-RECEPTOR; ATRIAL-FIBRILLATION; GENE REARRANGEMENT; SOMATIC MUTATION; CLINICAL-TRIAL; IBRUTINIB USE; ACTIVATION; BTK; RESISTANCE; MYD88;

D O I：

10.1016/j.hoc.2018.05.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Waldenstrom macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this article.

引用

页码：853 / +

页数：13

共 63 条

[1] An essential role for tyrosine kinase in the regulation of Bruton's B-cell apoptosis [J].

Anderson, JS ;

Teutsch, M ;

Dong, ZJ ;

Wortis, HH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10966-10971

[2]

[Anonymous], 57 ASH M ORL FL

[3]

[Anonymous], 57 ASH M ORL FL

[4]

[Anonymous], 59 ASH M ATL GA

[5]

[Anonymous], 58 ASH ANN M SAN DIE

[6]

[Anonymous], 2015, AACR 106 ANN M PHIL

[7]

[Anonymous], INT C MAL LYMPH BIEN

[8]

[Anonymous], 58 ASH M SAN DIEG CA

[9]

[Anonymous], 59 ASH M ATL GA DEC

[10]

[Anonymous], 57 ASH ANN M ORL FL

← 1 2 3 4 5 6 7 →